{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"17"},{"groupId":"OG001","value":"19"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"39"},{"groupId":"OG001","value":"42"}],"units":"Participants"}],"title":"Essential Thrombocythemia"},{"categories":[{"measurements":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"13"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"43"},{"groupId":"OG001","value":"44"}],"units":"Participants"}],"title":"Polycythemia Vera"}],"denoms":[{"counts":[{"groupId":"OG000","value":"82"},{"groupId":"OG001","value":"86"}],"units":"Participants"}],"description":"Number of participants with Complete Remission after 12 months of therapy assessed by hematologic response rates two strata of patients with high risk polycythemia vera (PV) or high risk essential thrombocythemia (ET). Complete remission means no evidence of disease.","groups":[{"description":"The subject received the PEGASYS at a dose level of 45 micrograms weekly and gradually increased to the maximum dose of 180 micrograms per week. The dose was administered by prefilled syringes and injected subcutaneously. Subjects received therapy for up to 12 months.\n\nAspirin: Subject asked to take 81 to 100mg per day for the 12 months of the study treatment.","id":"OG000","title":"PEGASYS"},{"description":"Subjects received a 500mg tablet to be taken twice daily for up to 12 months of treatment.\n\nAspirin: Subject asked to take 81 to 100mg per day for the 12 months of the study treatment.","id":"OG001","title":"Hydroxyurea"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"there were 82 participants in PEGASYS arm 39 with ET and 43 with PV, 86 in Hydroxyurea arm 42 with ET and 44 with PV","reportingStatus":"POSTED","timeFrame":"12 months","title":"Number of Participants With Complete Remission (CR)","type":"PRIMARY","unitOfMeasure":"Participants"}